Paul Norman
Concepts (759)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, KIR | 62 | 2026 | 123 | 11.480 |
Why?
| | Killer Cells, Natural | 57 | 2026 | 481 | 6.900 |
Why?
| | HLA Antigens | 24 | 2026 | 241 | 4.850 |
Why?
| | Haplotypes | 47 | 2026 | 506 | 4.570 |
Why?
| | Alleles | 52 | 2026 | 907 | 4.160 |
Why?
| | Histocompatibility Antigens Class I | 18 | 2026 | 207 | 4.090 |
Why?
| | Genes, MHC Class I | 12 | 2022 | 37 | 3.340 |
Why?
| | HLA-B Antigens | 21 | 2025 | 59 | 2.890 |
Why?
| | HLA-C Antigens | 19 | 2024 | 37 | 2.860 |
Why?
| | Polymorphism, Genetic | 33 | 2026 | 612 | 2.690 |
Why?
| | Genotype | 40 | 2026 | 1879 | 2.530 |
Why?
| | Receptors, KIR3DL1 | 13 | 2024 | 20 | 2.140 |
Why?
| | Selection, Genetic | 13 | 2026 | 269 | 2.040 |
Why?
| | Immunogenetics | 5 | 2024 | 8 | 1.970 |
Why?
| | Receptors, KIR2DL1 | 12 | 2024 | 22 | 1.950 |
Why?
| | Evolution, Molecular | 18 | 2022 | 502 | 1.680 |
Why?
| | Genetic Variation | 21 | 2026 | 996 | 1.500 |
Why?
| | High-Throughput Nucleotide Sequencing | 15 | 2025 | 539 | 1.300 |
Why?
| | Humans | 220 | 2026 | 146342 | 1.280 |
Why?
| | Amyotrophic Lateral Sclerosis | 7 | 2026 | 98 | 1.240 |
Why?
| | Genetics, Population | 13 | 2026 | 226 | 1.240 |
Why?
| | HLA-A Antigens | 11 | 2023 | 52 | 1.230 |
Why?
| | Gene Frequency | 21 | 2026 | 496 | 1.190 |
Why?
| | Receptors, KIR3DS1 | 4 | 2022 | 7 | 1.180 |
Why?
| | Employment | 4 | 2025 | 180 | 1.150 |
Why?
| | Receptors, Immunologic | 10 | 2021 | 210 | 1.080 |
Why?
| | Socioeconomic Factors | 8 | 2024 | 1327 | 1.060 |
Why?
| | Health Status Disparities | 6 | 2024 | 322 | 1.010 |
Why?
| | Gene Flow | 3 | 2026 | 91 | 1.010 |
Why?
| | Qualitative Research | 12 | 2026 | 1734 | 0.990 |
Why?
| | England | 13 | 2025 | 106 | 0.970 |
Why?
| | Chromosomes, Human, Pair 6 | 2 | 2025 | 51 | 0.960 |
Why?
| | Retirement | 2 | 2025 | 35 | 0.950 |
Why?
| | Genes, MHC Class II | 2 | 2017 | 77 | 0.940 |
Why?
| | United Kingdom | 14 | 2025 | 377 | 0.920 |
Why?
| | Poverty Areas | 3 | 2019 | 43 | 0.890 |
Why?
| | Software | 5 | 2026 | 676 | 0.880 |
Why?
| | Emergency Service, Hospital | 12 | 2026 | 2363 | 0.840 |
Why?
| | Sequence Deletion | 1 | 2025 | 190 | 0.840 |
Why?
| | Focus Groups | 5 | 2026 | 588 | 0.830 |
Why?
| | Adaptation, Psychological | 8 | 2026 | 721 | 0.830 |
Why?
| | Genome-Wide Association Study | 5 | 2026 | 1537 | 0.830 |
Why?
| | Medication Errors | 1 | 2024 | 86 | 0.810 |
Why?
| | Immunogenetic Phenomena | 2 | 2022 | 8 | 0.810 |
Why?
| | Genome, Human | 6 | 2025 | 431 | 0.800 |
Why?
| | Residence Characteristics | 3 | 2021 | 385 | 0.780 |
Why?
| | Genetic Predisposition to Disease | 15 | 2026 | 2488 | 0.750 |
Why?
| | Pre-Eclampsia | 3 | 2020 | 206 | 0.750 |
Why?
| | Ligands | 15 | 2023 | 678 | 0.750 |
Why?
| | Multimorbidity | 1 | 2023 | 65 | 0.740 |
Why?
| | Polymorphism, Single Nucleotide | 15 | 2026 | 2240 | 0.730 |
Why?
| | Herpesviridae | 1 | 2022 | 21 | 0.720 |
Why?
| | Complement C4 | 2 | 2025 | 31 | 0.720 |
Why?
| | Receptors, Natural Killer Cell | 6 | 2022 | 16 | 0.720 |
Why?
| | Minority Groups | 5 | 2024 | 286 | 0.690 |
Why?
| | Hematopoietic Stem Cell Transplantation | 7 | 2025 | 704 | 0.690 |
Why?
| | Primates | 3 | 2019 | 133 | 0.690 |
Why?
| | Quality of Life | 16 | 2025 | 3200 | 0.690 |
Why?
| | Binge Drinking | 2 | 2021 | 44 | 0.680 |
Why?
| | Herpesviridae Infections | 1 | 2023 | 147 | 0.680 |
Why?
| | Male | 80 | 2026 | 73396 | 0.670 |
Why?
| | Hearing Aids | 1 | 2021 | 45 | 0.670 |
Why?
| | Health Promotion | 6 | 2024 | 786 | 0.670 |
Why?
| | Patient Safety | 1 | 2024 | 352 | 0.650 |
Why?
| | Communicable Diseases | 1 | 2023 | 166 | 0.650 |
Why?
| | Cross-Sectional Studies | 17 | 2024 | 5899 | 0.650 |
Why?
| | DNA Copy Number Variations | 6 | 2025 | 192 | 0.650 |
Why?
| | Adult | 60 | 2026 | 41087 | 0.630 |
Why?
| | CD8-Positive T-Lymphocytes | 4 | 2023 | 931 | 0.620 |
Why?
| | Major Histocompatibility Complex | 4 | 2025 | 234 | 0.620 |
Why?
| | Mortality | 2 | 2014 | 375 | 0.610 |
Why?
| | Female | 85 | 2026 | 79499 | 0.610 |
Why?
| | Seizures | 4 | 2019 | 489 | 0.610 |
Why?
| | Censuses | 3 | 2017 | 33 | 0.610 |
Why?
| | Burns | 4 | 2026 | 365 | 0.610 |
Why?
| | Waiting Lists | 3 | 2026 | 251 | 0.600 |
Why?
| | Aortic Aneurysm, Abdominal | 3 | 2017 | 164 | 0.590 |
Why?
| | Somatoform Disorders | 2 | 2016 | 34 | 0.580 |
Why?
| | Hearing Loss | 1 | 2021 | 177 | 0.580 |
Why?
| | Middle Aged | 54 | 2026 | 36619 | 0.570 |
Why?
| | Histocompatibility Antigens Class II | 2 | 2023 | 365 | 0.560 |
Why?
| | Peptides | 4 | 2022 | 992 | 0.560 |
Why?
| | Point Mutation | 3 | 2017 | 232 | 0.550 |
Why?
| | Intensive Care Units | 1 | 2024 | 925 | 0.540 |
Why?
| | Receptors, KIR2DL4 | 3 | 2016 | 4 | 0.540 |
Why?
| | Heterozygote | 1 | 2019 | 311 | 0.530 |
Why?
| | Pan troglodytes | 9 | 2017 | 62 | 0.530 |
Why?
| | Motor Neuron Disease | 3 | 2025 | 21 | 0.520 |
Why?
| | Blood Vessel Prosthesis Implantation | 2 | 2022 | 219 | 0.520 |
Why?
| | Language | 1 | 2020 | 315 | 0.520 |
Why?
| | Psoriasis | 3 | 2024 | 110 | 0.510 |
Why?
| | Body Image | 4 | 2026 | 96 | 0.510 |
Why?
| | Health Status | 3 | 2025 | 827 | 0.500 |
Why?
| | Genotyping Techniques | 4 | 2025 | 74 | 0.500 |
Why?
| | Leukemia | 1 | 2019 | 246 | 0.490 |
Why?
| | Protein Binding | 10 | 2019 | 2244 | 0.490 |
Why?
| | Mucins | 1 | 2017 | 75 | 0.480 |
Why?
| | Rural Health Services | 3 | 2025 | 139 | 0.480 |
Why?
| | Linkage Disequilibrium | 10 | 2017 | 260 | 0.480 |
Why?
| | Quality Improvement | 4 | 2026 | 1354 | 0.460 |
Why?
| | Young Adult | 25 | 2026 | 14330 | 0.460 |
Why?
| | Blood Vessel Prosthesis | 2 | 2022 | 133 | 0.460 |
Why?
| | Population Dynamics | 2 | 2018 | 142 | 0.450 |
Why?
| | Energy Intake | 4 | 2026 | 507 | 0.450 |
Why?
| | Immunoglobulin Fc Fragments | 2 | 2015 | 41 | 0.450 |
Why?
| | Self Concept | 4 | 2026 | 257 | 0.450 |
Why?
| | Immunoglobulins | 4 | 2023 | 162 | 0.440 |
Why?
| | Weight Loss | 3 | 2019 | 858 | 0.440 |
Why?
| | Endovascular Procedures | 2 | 2022 | 390 | 0.440 |
Why?
| | Family Relations | 1 | 2015 | 87 | 0.440 |
Why?
| | Exons | 1 | 2016 | 361 | 0.420 |
Why?
| | Population | 1 | 2014 | 30 | 0.420 |
Why?
| | Longitudinal Studies | 11 | 2025 | 3017 | 0.410 |
Why?
| | Sequence Analysis, DNA | 8 | 2025 | 771 | 0.400 |
Why?
| | Aged | 31 | 2026 | 26432 | 0.400 |
Why?
| | Blood Flow Velocity | 1 | 2015 | 419 | 0.400 |
Why?
| | Wales | 5 | 2025 | 24 | 0.400 |
Why?
| | Receptors, KIR2DL2 | 5 | 2021 | 6 | 0.400 |
Why?
| | Receptors, KIR2DL3 | 6 | 2017 | 9 | 0.390 |
Why?
| | Terminally Ill | 1 | 2014 | 40 | 0.390 |
Why?
| | Diagnostic Self Evaluation | 1 | 2013 | 24 | 0.390 |
Why?
| | Immunity, Innate | 7 | 2024 | 844 | 0.390 |
Why?
| | HLA-DRB1 Chains | 4 | 2026 | 109 | 0.390 |
Why?
| | Behavior Therapy | 4 | 2023 | 291 | 0.380 |
Why?
| | Cell Line | 8 | 2019 | 2814 | 0.380 |
Why?
| | Malaria | 1 | 2013 | 73 | 0.370 |
Why?
| | Histocompatibility Testing | 4 | 2024 | 124 | 0.370 |
Why?
| | Overweight | 1 | 2017 | 614 | 0.370 |
Why?
| | Stents | 2 | 2022 | 554 | 0.360 |
Why?
| | T-Lymphocytes | 7 | 2026 | 2012 | 0.360 |
Why?
| | Empathy | 2 | 2024 | 184 | 0.360 |
Why?
| | Adolescent | 24 | 2026 | 22557 | 0.360 |
Why?
| | Recombinant Proteins | 1 | 2015 | 1361 | 0.350 |
Why?
| | Mortality, Premature | 1 | 2011 | 14 | 0.350 |
Why?
| | Attitude of Health Personnel | 4 | 2025 | 1219 | 0.340 |
Why?
| | Noninvasive Ventilation | 2 | 2025 | 66 | 0.340 |
Why?
| | Molecular Sequence Data | 14 | 2014 | 2838 | 0.340 |
Why?
| | Intention | 3 | 2021 | 187 | 0.330 |
Why?
| | Infant Mortality | 2 | 2024 | 127 | 0.330 |
Why?
| | Life Expectancy | 1 | 2011 | 72 | 0.330 |
Why?
| | Cytomegalovirus | 3 | 2024 | 172 | 0.330 |
Why?
| | Depression | 3 | 2023 | 1575 | 0.330 |
Why?
| | Thyroid Neoplasms | 2 | 2026 | 380 | 0.330 |
Why?
| | Universities | 3 | 2021 | 451 | 0.320 |
Why?
| | Life Style | 4 | 2017 | 496 | 0.320 |
Why?
| | Australia | 5 | 2024 | 291 | 0.320 |
Why?
| | Phylogeny | 13 | 2026 | 924 | 0.310 |
Why?
| | Emergency Medicine | 2 | 2024 | 280 | 0.310 |
Why?
| | Behcet Syndrome | 2 | 2021 | 19 | 0.310 |
Why?
| | Biological Evolution | 5 | 2019 | 471 | 0.310 |
Why?
| | Alcoholism | 1 | 2017 | 830 | 0.310 |
Why?
| | Cohort Studies | 9 | 2026 | 6077 | 0.310 |
Why?
| | Health Behavior | 6 | 2025 | 802 | 0.300 |
Why?
| | Epitopes | 8 | 2019 | 479 | 0.300 |
Why?
| | Patient Compliance | 3 | 2025 | 589 | 0.300 |
Why?
| | Amino Acid Sequence | 9 | 2019 | 2092 | 0.300 |
Why?
| | Infant, Newborn | 9 | 2026 | 6460 | 0.300 |
Why?
| | Cause of Death | 1 | 2011 | 456 | 0.290 |
Why?
| | Malnutrition | 2 | 2021 | 87 | 0.290 |
Why?
| | Patient Acceptance of Health Care | 3 | 2026 | 881 | 0.290 |
Why?
| | Recombination, Genetic | 2 | 2010 | 202 | 0.290 |
Why?
| | Models, Molecular | 5 | 2019 | 1573 | 0.290 |
Why?
| | Health Personnel | 4 | 2025 | 754 | 0.280 |
Why?
| | Pakistan | 2 | 2026 | 83 | 0.280 |
Why?
| | Infant | 10 | 2026 | 10114 | 0.280 |
Why?
| | Cytomegalovirus Infections | 2 | 2024 | 206 | 0.280 |
Why?
| | Meiosis | 1 | 2009 | 102 | 0.280 |
Why?
| | Newfoundland and Labrador | 5 | 2026 | 5 | 0.270 |
Why?
| | Antigens, CD | 5 | 2017 | 560 | 0.270 |
Why?
| | India | 2 | 2026 | 213 | 0.270 |
Why?
| | Child | 14 | 2026 | 22693 | 0.270 |
Why?
| | Urban Population | 1 | 2011 | 497 | 0.270 |
Why?
| | Life Change Events | 2 | 2019 | 144 | 0.270 |
Why?
| | Alcohol Drinking | 4 | 2021 | 850 | 0.260 |
Why?
| | Rural Population | 2 | 2018 | 677 | 0.260 |
Why?
| | Chronic Disease | 1 | 2014 | 1827 | 0.260 |
Why?
| | Students | 3 | 2021 | 649 | 0.260 |
Why?
| | Genomics | 6 | 2025 | 853 | 0.260 |
Why?
| | HLA-DQ alpha-Chains | 2 | 2026 | 17 | 0.260 |
Why?
| | Object Attachment | 2 | 2019 | 48 | 0.260 |
Why?
| | China | 3 | 2024 | 280 | 0.250 |
Why?
| | Oceania | 2 | 2024 | 5 | 0.250 |
Why?
| | HLA-DQ beta-Chains | 2 | 2026 | 58 | 0.250 |
Why?
| | Homozygote | 2 | 2025 | 197 | 0.250 |
Why?
| | Income | 2 | 2019 | 206 | 0.250 |
Why?
| | Physicians | 2 | 2026 | 955 | 0.250 |
Why?
| | Signal Transduction | 4 | 2019 | 5246 | 0.250 |
Why?
| | Caregivers | 5 | 2026 | 1080 | 0.250 |
Why?
| | Immune System | 2 | 2019 | 181 | 0.250 |
Why?
| | Multigene Family | 3 | 2018 | 210 | 0.240 |
Why?
| | Papua New Guinea | 1 | 2026 | 10 | 0.240 |
Why?
| | Egypt | 2 | 2023 | 13 | 0.240 |
Why?
| | Obesity | 2 | 2017 | 3131 | 0.240 |
Why?
| | Centromere | 3 | 2025 | 62 | 0.240 |
Why?
| | HLA-A24 Antigen | 2 | 2024 | 5 | 0.230 |
Why?
| | Self-Management | 2 | 2019 | 207 | 0.230 |
Why?
| | Phenotype | 8 | 2024 | 3206 | 0.230 |
Why?
| | Amino Acid Substitution | 5 | 2016 | 297 | 0.230 |
Why?
| | Adenocarcinoma, Follicular | 1 | 2026 | 43 | 0.230 |
Why?
| | Animals | 29 | 2025 | 38106 | 0.230 |
Why?
| | Codon | 2 | 2016 | 92 | 0.230 |
Why?
| | Virus Activation | 2 | 2024 | 97 | 0.230 |
Why?
| | Fatigue Syndrome, Chronic | 1 | 2025 | 19 | 0.230 |
Why?
| | Thymus Gland | 2 | 2024 | 310 | 0.230 |
Why?
| | Celiac Disease | 2 | 2026 | 285 | 0.230 |
Why?
| | Patient Satisfaction | 4 | 2026 | 706 | 0.220 |
Why?
| | Acceptance and Commitment Therapy | 1 | 2026 | 36 | 0.220 |
Why?
| | Industry | 1 | 2025 | 43 | 0.220 |
Why?
| | Smoking | 5 | 2019 | 1486 | 0.220 |
Why?
| | Patient Transfer | 2 | 2026 | 224 | 0.220 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2026 | 156 | 0.210 |
Why?
| | Rural Health | 1 | 2025 | 87 | 0.210 |
Why?
| | Mucosal-Associated Invariant T Cells | 1 | 2025 | 39 | 0.210 |
Why?
| | Hominidae | 2 | 2019 | 89 | 0.210 |
Why?
| | Body Mass Index | 1 | 2013 | 2458 | 0.210 |
Why?
| | Occupations | 1 | 2024 | 50 | 0.210 |
Why?
| | Interpersonal Relations | 2 | 2019 | 387 | 0.210 |
Why?
| | Attitude to Health | 3 | 2019 | 421 | 0.210 |
Why?
| | Capacity Building | 1 | 2025 | 61 | 0.210 |
Why?
| | Antigens, Neoplasm | 1 | 2026 | 271 | 0.210 |
Why?
| | Th17 Cells | 1 | 2025 | 103 | 0.210 |
Why?
| | Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2024 | 22 | 0.210 |
Why?
| | Motivation | 2 | 2026 | 605 | 0.200 |
Why?
| | Surveys and Questionnaires | 9 | 2026 | 6073 | 0.200 |
Why?
| | Iodine Radioisotopes | 1 | 2024 | 139 | 0.200 |
Why?
| | Nutrition Therapy | 2 | 2025 | 37 | 0.200 |
Why?
| | Myocardial Infarction | 2 | 2023 | 1215 | 0.200 |
Why?
| | Pedigree | 1 | 2025 | 512 | 0.200 |
Why?
| | Arabs | 2 | 2020 | 9 | 0.200 |
Why?
| | Child, Preschool | 9 | 2026 | 11913 | 0.200 |
Why?
| | Phenylurea Compounds | 1 | 2024 | 122 | 0.200 |
Why?
| | Quinolines | 2 | 2024 | 191 | 0.200 |
Why?
| | Alopecia Areata | 1 | 2023 | 12 | 0.190 |
Why?
| | Immunity, Cellular | 1 | 2005 | 277 | 0.190 |
Why?
| | HLA-DP beta-Chains | 1 | 2023 | 88 | 0.190 |
Why?
| | Gene Dosage | 3 | 2021 | 146 | 0.190 |
Why?
| | Canada | 4 | 2025 | 432 | 0.190 |
Why?
| | Parkinson Disease | 2 | 2020 | 614 | 0.190 |
Why?
| | Iran | 2 | 2020 | 39 | 0.190 |
Why?
| | Efficiency, Organizational | 2 | 2025 | 144 | 0.190 |
Why?
| | Unemployment | 1 | 2022 | 43 | 0.190 |
Why?
| | Cardiovascular Diseases | 3 | 2021 | 2219 | 0.180 |
Why?
| | Time Factors | 11 | 2026 | 7109 | 0.180 |
Why?
| | Incidence | 5 | 2020 | 2936 | 0.180 |
Why?
| | Registries | 4 | 2021 | 2400 | 0.180 |
Why?
| | Computational Biology | 2 | 2025 | 678 | 0.180 |
Why?
| | Health Services Research | 1 | 2025 | 390 | 0.180 |
Why?
| | Transplantation Conditioning | 1 | 2024 | 193 | 0.180 |
Why?
| | Colon | 1 | 2025 | 304 | 0.180 |
Why?
| | Perception | 1 | 2025 | 373 | 0.180 |
Why?
| | Lymphocyte Activation | 5 | 2021 | 1137 | 0.180 |
Why?
| | Leukocytes | 1 | 2004 | 301 | 0.180 |
Why?
| | Sequence Alignment | 3 | 2021 | 360 | 0.180 |
Why?
| | Africa, Southern | 2 | 2021 | 6 | 0.180 |
Why?
| | Colitis | 1 | 2025 | 283 | 0.180 |
Why?
| | Social Stigma | 1 | 2024 | 174 | 0.180 |
Why?
| | Transplantation, Homologous | 5 | 2025 | 416 | 0.180 |
Why?
| | Telomere | 4 | 2025 | 300 | 0.180 |
Why?
| | Toll-Like Receptor 3 | 1 | 2021 | 29 | 0.180 |
Why?
| | Health | 1 | 2022 | 81 | 0.170 |
Why?
| | Age Factors | 5 | 2018 | 3347 | 0.170 |
Why?
| | Multilevel Analysis | 1 | 2021 | 35 | 0.170 |
Why?
| | Eczema | 1 | 2022 | 66 | 0.170 |
Why?
| | Longevity | 1 | 2023 | 179 | 0.170 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2023 | 330 | 0.170 |
Why?
| | New Zealand | 3 | 2018 | 56 | 0.170 |
Why?
| | Genomic Structural Variation | 1 | 2021 | 13 | 0.170 |
Why?
| | Yersinia pestis | 1 | 2021 | 45 | 0.170 |
Why?
| | Mindfulness | 1 | 2023 | 134 | 0.160 |
Why?
| | Protein Interaction Domains and Motifs | 2 | 2019 | 145 | 0.160 |
Why?
| | Malaysia | 1 | 2020 | 15 | 0.160 |
Why?
| | Professional Practice Location | 1 | 2021 | 26 | 0.160 |
Why?
| | Interviews as Topic | 4 | 2026 | 930 | 0.160 |
Why?
| | HLA-D Antigens | 1 | 2021 | 30 | 0.160 |
Why?
| | Nutritionists | 1 | 2021 | 24 | 0.160 |
Why?
| | Nutritional Support | 1 | 2021 | 39 | 0.160 |
Why?
| | Plague | 1 | 2021 | 60 | 0.160 |
Why?
| | Physical Appearance, Body | 3 | 2024 | 4 | 0.160 |
Why?
| | Patient-Centered Care | 1 | 2026 | 553 | 0.160 |
Why?
| | Peripheral Arterial Disease | 2 | 2018 | 507 | 0.160 |
Why?
| | Clinical Protocols | 2 | 2019 | 282 | 0.160 |
Why?
| | Hearing Tests | 1 | 2020 | 41 | 0.160 |
Why?
| | Base Sequence | 4 | 2016 | 2123 | 0.160 |
Why?
| | Artificial Intelligence | 1 | 2025 | 389 | 0.150 |
Why?
| | Exercise | 5 | 2019 | 2213 | 0.150 |
Why?
| | Indians, North American | 2 | 2015 | 527 | 0.150 |
Why?
| | Mentoring | 1 | 2023 | 166 | 0.150 |
Why?
| | Multiple Sclerosis | 1 | 2025 | 435 | 0.150 |
Why?
| | Natural Cytotoxicity Triggering Receptor 2 | 1 | 2019 | 2 | 0.150 |
Why?
| | Pregnancy | 6 | 2020 | 7230 | 0.150 |
Why?
| | Transportation | 1 | 2019 | 54 | 0.150 |
Why?
| | Clathrin Heavy Chains | 1 | 2019 | 3 | 0.150 |
Why?
| | HLA-DP Antigens | 1 | 2019 | 32 | 0.150 |
Why?
| | Protozoan Infections | 1 | 2019 | 11 | 0.150 |
Why?
| | Diet, Diabetic | 1 | 2019 | 33 | 0.150 |
Why?
| | Hearing | 1 | 2020 | 102 | 0.150 |
Why?
| | Intestinal Mucosa | 1 | 2025 | 666 | 0.150 |
Why?
| | Case-Control Studies | 7 | 2026 | 3647 | 0.150 |
Why?
| | B-Lymphocytes | 4 | 2017 | 887 | 0.140 |
Why?
| | Diabetic Foot | 1 | 2019 | 25 | 0.140 |
Why?
| | Receptors, Antigen, T-Cell | 3 | 2024 | 677 | 0.140 |
Why?
| | Phylogeography | 1 | 2019 | 52 | 0.140 |
Why?
| | Bicycling | 1 | 2019 | 117 | 0.140 |
Why?
| | Prevalence | 5 | 2019 | 2861 | 0.140 |
Why?
| | Diet | 4 | 2019 | 1273 | 0.140 |
Why?
| | Aggression | 1 | 2020 | 171 | 0.140 |
Why?
| | Receptors, Cell Surface | 1 | 2001 | 371 | 0.140 |
Why?
| | Sex Factors | 4 | 2019 | 2107 | 0.140 |
Why?
| | Parents | 2 | 2024 | 1394 | 0.140 |
Why?
| | Cluster Analysis | 2 | 2017 | 496 | 0.140 |
Why?
| | Indians, South American | 2 | 2009 | 23 | 0.140 |
Why?
| | Africa South of the Sahara | 2 | 2019 | 56 | 0.140 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2018 | 56 | 0.140 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2024 | 992 | 0.130 |
Why?
| | ZAP-70 Protein-Tyrosine Kinase | 1 | 2017 | 10 | 0.130 |
Why?
| | Syk Kinase | 1 | 2017 | 19 | 0.130 |
Why?
| | Leukemia, Myeloid, Acute | 2 | 2024 | 702 | 0.130 |
Why?
| | Middle East | 1 | 2017 | 18 | 0.130 |
Why?
| | Eye Diseases | 1 | 2019 | 100 | 0.130 |
Why?
| | Flow Cytometry | 7 | 2018 | 1163 | 0.130 |
Why?
| | Risk Factors | 12 | 2025 | 10921 | 0.130 |
Why?
| | Names | 1 | 2017 | 15 | 0.130 |
Why?
| | Burnout, Professional | 1 | 2024 | 493 | 0.130 |
Why?
| | Polymerase Chain Reaction | 6 | 2017 | 1031 | 0.130 |
Why?
| | Binding Sites | 6 | 2015 | 1309 | 0.130 |
Why?
| | Structure-Activity Relationship | 1 | 2019 | 563 | 0.130 |
Why?
| | Lymphocyte Subsets | 3 | 2009 | 79 | 0.130 |
Why?
| | Walking | 2 | 2019 | 546 | 0.130 |
Why?
| | Air Pollution | 1 | 2021 | 314 | 0.130 |
Why?
| | Genetic Testing | 4 | 2002 | 492 | 0.130 |
Why?
| | Pan paniscus | 1 | 2017 | 4 | 0.130 |
Why?
| | Thrombospondin 1 | 1 | 2017 | 27 | 0.130 |
Why?
| | Contig Mapping | 1 | 2017 | 10 | 0.130 |
Why?
| | Multifactorial Inheritance | 1 | 2019 | 243 | 0.130 |
Why?
| | Protein Structure, Tertiary | 5 | 2015 | 834 | 0.130 |
Why?
| | Immunodominant Epitopes | 1 | 2017 | 27 | 0.130 |
Why?
| | Gene Expression Regulation | 2 | 2013 | 2599 | 0.130 |
Why?
| | Pongo | 1 | 2017 | 7 | 0.130 |
Why?
| | Aorta, Abdominal | 1 | 2017 | 51 | 0.130 |
Why?
| | Models, Genetic | 4 | 2015 | 540 | 0.120 |
Why?
| | Osteosarcoma | 1 | 2018 | 100 | 0.120 |
Why?
| | Women's Health | 1 | 2019 | 317 | 0.120 |
Why?
| | Alcoholic Beverages | 1 | 2017 | 32 | 0.120 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2017 | 103 | 0.120 |
Why?
| | Epilepsy | 2 | 2019 | 400 | 0.120 |
Why?
| | Virus Diseases | 1 | 2019 | 219 | 0.120 |
Why?
| | Angiotensin II | 1 | 2017 | 102 | 0.120 |
Why?
| | Sarcoma, Ewing | 1 | 2018 | 103 | 0.120 |
Why?
| | Reference Standards | 1 | 2017 | 176 | 0.120 |
Why?
| | Health Services Needs and Demand | 1 | 2019 | 287 | 0.120 |
Why?
| | Anxiety | 3 | 2023 | 1125 | 0.120 |
Why?
| | Antimicrobial Stewardship | 1 | 2019 | 136 | 0.120 |
Why?
| | Allied Health Personnel | 1 | 2016 | 54 | 0.120 |
Why?
| | Aged, 80 and over | 7 | 2024 | 8391 | 0.120 |
Why?
| | Logistic Models | 3 | 2021 | 2126 | 0.120 |
Why?
| | Open Reading Frames | 1 | 2017 | 130 | 0.120 |
Why?
| | Environmental Exposure | 1 | 2021 | 578 | 0.120 |
Why?
| | Molecular Typing | 1 | 2016 | 21 | 0.120 |
Why?
| | Herpesvirus 4, Human | 1 | 2017 | 172 | 0.120 |
Why?
| | Placentation | 2 | 2016 | 52 | 0.120 |
Why?
| | Feeding Behavior | 2 | 2019 | 692 | 0.120 |
Why?
| | Self Care | 2 | 2016 | 396 | 0.120 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 516 | 0.120 |
Why?
| | HIV-1 | 1 | 2022 | 913 | 0.120 |
Why?
| | Protein Conformation | 1 | 2019 | 916 | 0.110 |
Why?
| | Crohn Disease | 1 | 2019 | 250 | 0.110 |
Why?
| | Gene Expression | 4 | 2018 | 1463 | 0.110 |
Why?
| | Donor Selection | 1 | 2016 | 66 | 0.110 |
Why?
| | Dissociative Disorders | 1 | 2015 | 30 | 0.110 |
Why?
| | Sf9 Cells | 1 | 2015 | 11 | 0.110 |
Why?
| | Age Distribution | 2 | 2018 | 399 | 0.110 |
Why?
| | Spodoptera | 1 | 2015 | 39 | 0.110 |
Why?
| | Sex Distribution | 2 | 2018 | 382 | 0.110 |
Why?
| | Baculoviridae | 1 | 2015 | 44 | 0.110 |
Why?
| | Chest Pain | 1 | 2016 | 100 | 0.110 |
Why?
| | Human Migration | 1 | 2015 | 26 | 0.110 |
Why?
| | Curriculum | 1 | 2022 | 1079 | 0.110 |
Why?
| | Potassium Channels, Inwardly Rectifying | 1 | 2015 | 46 | 0.110 |
Why?
| | Bone Neoplasms | 1 | 2018 | 272 | 0.110 |
Why?
| | Social Class | 1 | 2017 | 260 | 0.110 |
Why?
| | Research Report | 1 | 2015 | 89 | 0.110 |
Why?
| | Adolescent Behavior | 1 | 2020 | 486 | 0.110 |
Why?
| | Amino Acid Motifs | 5 | 2019 | 218 | 0.110 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 387 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 379 | 0.110 |
Why?
| | Insecta | 1 | 2015 | 73 | 0.110 |
Why?
| | Polynesia | 1 | 2014 | 3 | 0.110 |
Why?
| | Isoantibodies | 1 | 1995 | 58 | 0.110 |
Why?
| | Biological Assay | 1 | 2015 | 133 | 0.110 |
Why?
| | Simian Immunodeficiency Virus | 1 | 2015 | 94 | 0.110 |
Why?
| | Receptors, KIR3DL2 | 2 | 2015 | 2 | 0.110 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 1998 | 0.100 |
Why?
| | DNA | 3 | 2021 | 1421 | 0.100 |
Why?
| | HLA-DQ Antigens | 2 | 2026 | 171 | 0.100 |
Why?
| | Muscle Weakness | 1 | 2014 | 93 | 0.100 |
Why?
| | Risk Reduction Behavior | 1 | 2015 | 220 | 0.100 |
Why?
| | Mammals | 1 | 2015 | 288 | 0.100 |
Why?
| | Protein Folding | 1 | 2015 | 281 | 0.100 |
Why?
| | Glucose | 1 | 2019 | 1053 | 0.100 |
Why?
| | Kidney Transplantation | 2 | 2003 | 735 | 0.100 |
Why?
| | Chromosomes, Human, Pair 19 | 2 | 2004 | 28 | 0.100 |
Why?
| | Prospective Studies | 7 | 2024 | 8123 | 0.100 |
Why?
| | Tissue Donors | 4 | 2024 | 425 | 0.100 |
Why?
| | Counseling | 1 | 2016 | 406 | 0.100 |
Why?
| | Conserved Sequence | 2 | 2011 | 242 | 0.100 |
Why?
| | Species Specificity | 4 | 2017 | 543 | 0.100 |
Why?
| | Prostatic Neoplasms | 1 | 2020 | 972 | 0.100 |
Why?
| | Cell Differentiation | 4 | 2024 | 1982 | 0.090 |
Why?
| | Thinness | 1 | 2013 | 100 | 0.090 |
Why?
| | Interrupted Time Series Analysis | 2 | 2026 | 73 | 0.090 |
Why?
| | Seals, Earless | 1 | 2012 | 5 | 0.090 |
Why?
| | DNA Primers | 4 | 2018 | 487 | 0.090 |
Why?
| | Exome | 1 | 2014 | 233 | 0.090 |
Why?
| | Genetics, Medical | 3 | 2019 | 23 | 0.090 |
Why?
| | Anxiety Disorders | 1 | 2016 | 354 | 0.090 |
Why?
| | Metagenomics | 1 | 2014 | 154 | 0.090 |
Why?
| | Treatment Outcome | 6 | 2025 | 11821 | 0.090 |
Why?
| | Hematopoietic Stem Cells | 1 | 2016 | 432 | 0.090 |
Why?
| | Hepatitis C | 1 | 2015 | 251 | 0.090 |
Why?
| | Stress, Psychological | 2 | 2016 | 1171 | 0.090 |
Why?
| | Graft Survival | 1 | 1995 | 523 | 0.090 |
Why?
| | Saliva | 1 | 2014 | 256 | 0.090 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2019 | 3930 | 0.090 |
Why?
| | Environment | 1 | 2013 | 299 | 0.090 |
Why?
| | CD56 Antigen | 2 | 2009 | 34 | 0.090 |
Why?
| | Scotland | 1 | 2011 | 54 | 0.090 |
Why?
| | Nervous System Diseases | 1 | 2014 | 288 | 0.090 |
Why?
| | Health Surveys | 1 | 2013 | 511 | 0.080 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 1195 | 0.080 |
Why?
| | Graft Rejection | 1 | 1995 | 516 | 0.080 |
Why?
| | Self Efficacy | 1 | 2015 | 418 | 0.080 |
Why?
| | Genes, Overlapping | 1 | 2011 | 2 | 0.080 |
Why?
| | Interferon-gamma | 2 | 2017 | 781 | 0.080 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily C | 3 | 2017 | 9 | 0.080 |
Why?
| | Internet | 1 | 2015 | 660 | 0.080 |
Why?
| | Hybridization, Genetic | 1 | 2011 | 75 | 0.080 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2017 | 640 | 0.080 |
Why?
| | Immunoglobulin G | 1 | 1995 | 901 | 0.080 |
Why?
| | Triage | 2 | 2026 | 243 | 0.080 |
Why?
| | North America | 2 | 2021 | 300 | 0.080 |
Why?
| | Mass Spectrometry | 1 | 2013 | 729 | 0.080 |
Why?
| | Europe | 2 | 2021 | 421 | 0.080 |
Why?
| | Cost-Benefit Analysis | 3 | 2025 | 640 | 0.080 |
Why?
| | Gene Conversion | 1 | 2009 | 7 | 0.080 |
Why?
| | Graft vs Host Disease | 2 | 2025 | 283 | 0.080 |
Why?
| | Family | 1 | 2014 | 690 | 0.080 |
Why?
| | Gene Products, nef | 1 | 2009 | 12 | 0.080 |
Why?
| | Transforming Growth Factor beta | 1 | 2012 | 467 | 0.080 |
Why?
| | Receptors, IgG | 2 | 2014 | 77 | 0.070 |
Why?
| | Organ Transplantation | 1 | 2013 | 244 | 0.070 |
Why?
| | Hypoglycemic Agents | 1 | 2019 | 1412 | 0.070 |
Why?
| | Self Report | 1 | 2014 | 870 | 0.070 |
Why?
| | Hospitals | 1 | 2014 | 738 | 0.070 |
Why?
| | Hospitalization | 2 | 2023 | 2475 | 0.070 |
Why?
| | Histocompatibility Antigens | 1 | 2009 | 102 | 0.070 |
Why?
| | Health Services Accessibility | 1 | 2017 | 1107 | 0.070 |
Why?
| | Algorithms | 3 | 2024 | 1849 | 0.070 |
Why?
| | Antigens, Bacterial | 1 | 2009 | 125 | 0.070 |
Why?
| | Nutritional Status | 2 | 2021 | 346 | 0.070 |
Why?
| | Africa | 3 | 2019 | 119 | 0.070 |
Why?
| | Insulin | 1 | 2019 | 2525 | 0.070 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2623 | 0.070 |
Why?
| | Homocysteine | 1 | 2008 | 152 | 0.070 |
Why?
| | Anti-Bacterial Agents | 1 | 2019 | 1942 | 0.070 |
Why?
| | Regression Analysis | 2 | 2021 | 999 | 0.070 |
Why?
| | Databases, Factual | 1 | 2013 | 1493 | 0.070 |
Why?
| | Mutagenesis, Site-Directed | 4 | 2009 | 371 | 0.070 |
Why?
| | Exotoxins | 1 | 2007 | 16 | 0.060 |
Why?
| | Breast Neoplasms | 4 | 2002 | 2418 | 0.060 |
Why?
| | Lung Neoplasms | 1 | 2020 | 2675 | 0.060 |
Why?
| | Polymorphism, Single-Stranded Conformational | 2 | 2004 | 26 | 0.060 |
Why?
| | Namibia | 1 | 2026 | 1 | 0.060 |
Why?
| | Botswana | 1 | 2026 | 11 | 0.060 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2007 | 382 | 0.060 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2015 | 1408 | 0.060 |
Why?
| | Receptors, Fc | 1 | 2007 | 54 | 0.060 |
Why?
| | Delivery of Health Care | 2 | 2025 | 947 | 0.060 |
Why?
| | HIV Infections | 1 | 2022 | 3215 | 0.060 |
Why?
| | Genetic Counseling | 3 | 2002 | 82 | 0.060 |
Why?
| | Risk | 3 | 2019 | 920 | 0.060 |
Why?
| | Disease Models, Animal | 4 | 2025 | 4580 | 0.060 |
Why?
| | Neoplasms | 2 | 2017 | 2954 | 0.060 |
Why?
| | Thyroglobulin | 1 | 2026 | 28 | 0.060 |
Why?
| | Brazil | 1 | 2026 | 179 | 0.060 |
Why?
| | Immunoglobulin A | 1 | 2007 | 205 | 0.060 |
Why?
| | HLA-DR Antigens | 2 | 2006 | 211 | 0.060 |
Why?
| | Trinidad and Tobago | 2 | 2002 | 5 | 0.060 |
Why?
| | Genetic Loci | 2 | 2019 | 273 | 0.060 |
Why?
| | Norway | 1 | 2025 | 41 | 0.060 |
Why?
| | Depressive Disorder | 1 | 2008 | 361 | 0.060 |
Why?
| | Ireland | 1 | 2025 | 33 | 0.060 |
Why?
| | Equivalence Trials as Topic | 1 | 2025 | 35 | 0.060 |
Why?
| | Severity of Illness Index | 3 | 2021 | 2921 | 0.060 |
Why?
| | Mice | 5 | 2025 | 18297 | 0.060 |
Why?
| | Jurkat Cells | 2 | 2019 | 115 | 0.060 |
Why?
| | INDEL Mutation | 1 | 2025 | 21 | 0.060 |
Why?
| | Kinetochores | 1 | 2025 | 52 | 0.060 |
Why?
| | Palliative Care | 1 | 2014 | 1032 | 0.050 |
Why?
| | Cells, Cultured | 3 | 2017 | 4118 | 0.050 |
Why?
| | Stroke | 1 | 2014 | 1287 | 0.050 |
Why?
| | Recurrence | 2 | 2021 | 1133 | 0.050 |
Why?
| | Mice, Knockout | 2 | 2025 | 3125 | 0.050 |
Why?
| | Models, Statistical | 2 | 2019 | 669 | 0.050 |
Why?
| | Cell Line, Tumor | 4 | 2015 | 3545 | 0.050 |
Why?
| | Histocompatibility | 1 | 2003 | 20 | 0.050 |
Why?
| | Whole Genome Sequencing | 1 | 2025 | 183 | 0.050 |
Why?
| | HeLa Cells | 2 | 2015 | 636 | 0.050 |
Why?
| | Mice, Inbred C57BL | 2 | 2025 | 6034 | 0.050 |
Why?
| | Lymphocyte Depletion | 1 | 2024 | 135 | 0.050 |
Why?
| | Leukocyte Immunoglobulin-like Receptor B1 | 1 | 2003 | 2 | 0.050 |
Why?
| | Prognosis | 2 | 2025 | 4351 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2025 | 417 | 0.050 |
Why?
| | Microsatellite Repeats | 1 | 2004 | 159 | 0.050 |
Why?
| | Neoplasm Proteins | 2 | 2004 | 444 | 0.050 |
Why?
| | Granzymes | 1 | 2023 | 51 | 0.050 |
Why?
| | Cell Communication | 1 | 2005 | 327 | 0.050 |
Why?
| | Lymphocytes | 1 | 2005 | 379 | 0.050 |
Why?
| | Staphylococcus aureus | 1 | 2007 | 459 | 0.050 |
Why?
| | Human Immunodeficiency Virus Proteins | 1 | 2022 | 6 | 0.050 |
Why?
| | Gene Library | 2 | 2014 | 121 | 0.050 |
Why?
| | Viral Regulatory and Accessory Proteins | 1 | 2022 | 27 | 0.050 |
Why?
| | Africa, Western | 1 | 2002 | 21 | 0.050 |
Why?
| | Chromosomes, Human | 1 | 2002 | 45 | 0.040 |
Why?
| | Bangladesh | 1 | 2002 | 64 | 0.040 |
Why?
| | Pandemics | 2 | 2021 | 1707 | 0.040 |
Why?
| | Risk Assessment | 4 | 2019 | 3712 | 0.040 |
Why?
| | Cloning, Molecular | 2 | 2014 | 526 | 0.040 |
Why?
| | Software Design | 1 | 2021 | 25 | 0.040 |
Why?
| | Databases, Nucleic Acid | 1 | 2021 | 39 | 0.040 |
Why?
| | Quantitative Trait, Heritable | 1 | 2002 | 119 | 0.040 |
Why?
| | Cytokines | 2 | 2025 | 2081 | 0.040 |
Why?
| | Hydroxychloroquine | 1 | 2021 | 65 | 0.040 |
Why?
| | Thailand | 1 | 2001 | 20 | 0.040 |
Why?
| | Single-Cell Analysis | 1 | 2024 | 370 | 0.040 |
Why?
| | Nutrition Assessment | 1 | 2021 | 90 | 0.040 |
Why?
| | Odds Ratio | 2 | 2017 | 1077 | 0.040 |
Why?
| | Twins | 1 | 2001 | 156 | 0.040 |
Why?
| | Geography | 1 | 2021 | 187 | 0.040 |
Why?
| | Bacterial Proteins | 1 | 2007 | 980 | 0.040 |
Why?
| | Confidence Intervals | 1 | 2021 | 329 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2025 | 712 | 0.040 |
Why?
| | Cholesterol, HDL | 1 | 2021 | 201 | 0.040 |
Why?
| | Prosthesis Design | 1 | 2022 | 358 | 0.040 |
Why?
| | Length of Stay | 1 | 2026 | 1358 | 0.040 |
Why?
| | Breathing Exercises | 1 | 2019 | 21 | 0.040 |
Why?
| | Genetic Markers | 1 | 2001 | 340 | 0.040 |
Why?
| | Leadership | 1 | 2024 | 414 | 0.040 |
Why?
| | Respiratory Muscles | 1 | 2019 | 36 | 0.040 |
Why?
| | Adolescent Nutritional Physiological Phenomena | 1 | 2019 | 29 | 0.040 |
Why?
| | Electric Impedance | 1 | 2019 | 108 | 0.040 |
Why?
| | Deglutition | 1 | 2019 | 73 | 0.040 |
Why?
| | Patient Acuity | 1 | 2019 | 46 | 0.040 |
Why?
| | Autophagy | 1 | 2021 | 290 | 0.040 |
Why?
| | Communication | 1 | 2026 | 980 | 0.040 |
Why?
| | Hospital Units | 1 | 2019 | 32 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2021 | 750 | 0.040 |
Why?
| | Cytotoxicity Tests, Immunologic | 2 | 2009 | 39 | 0.040 |
Why?
| | Hospitals, Rural | 1 | 2019 | 49 | 0.040 |
Why?
| | Nucleic Acid Denaturation | 1 | 2018 | 32 | 0.040 |
Why?
| | Group Processes | 1 | 2019 | 62 | 0.040 |
Why?
| | Ketones | 1 | 2019 | 51 | 0.040 |
Why?
| | Monitoring, Ambulatory | 1 | 2019 | 88 | 0.040 |
Why?
| | Hospitals, Community | 1 | 2019 | 68 | 0.040 |
Why?
| | Research Design | 1 | 2025 | 1143 | 0.040 |
Why?
| | Hepatitis B | 1 | 2019 | 66 | 0.040 |
Why?
| | Mutation | 3 | 2020 | 4093 | 0.040 |
Why?
| | Western Australia | 1 | 2018 | 8 | 0.030 |
Why?
| | Limit of Detection | 1 | 2018 | 92 | 0.030 |
Why?
| | Triglycerides | 1 | 2021 | 527 | 0.030 |
Why?
| | Cough | 1 | 2019 | 123 | 0.030 |
Why?
| | Chromosome Mapping | 2 | 2014 | 508 | 0.030 |
Why?
| | Environmental Monitoring | 1 | 2021 | 346 | 0.030 |
Why?
| | Posture | 1 | 2019 | 182 | 0.030 |
Why?
| | Disease Progression | 2 | 2017 | 2867 | 0.030 |
Why?
| | Parenting | 1 | 2022 | 309 | 0.030 |
Why?
| | T-Lymphocyte Subsets | 1 | 2000 | 416 | 0.030 |
Why?
| | Ankle Brachial Index | 1 | 2018 | 41 | 0.030 |
Why?
| | Particulate Matter | 1 | 2021 | 328 | 0.030 |
Why?
| | Biomarkers | 2 | 2021 | 4340 | 0.030 |
Why?
| | Body Height | 1 | 2019 | 205 | 0.030 |
Why?
| | Narration | 1 | 2019 | 82 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2024 | 983 | 0.030 |
Why?
| | Tertiary Care Centers | 1 | 2019 | 196 | 0.030 |
Why?
| | Deglutition Disorders | 1 | 2019 | 159 | 0.030 |
Why?
| | Demography | 2 | 2013 | 274 | 0.030 |
Why?
| | Health Care Surveys | 1 | 2019 | 541 | 0.030 |
Why?
| | Low Density Lipoprotein Receptor-Related Protein-1 | 1 | 2017 | 12 | 0.030 |
Why?
| | Collagen Type III | 1 | 2017 | 15 | 0.030 |
Why?
| | Arthritis, Rheumatoid | 1 | 2006 | 1185 | 0.030 |
Why?
| | Butyrophilins | 1 | 2017 | 5 | 0.030 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily K | 1 | 2017 | 7 | 0.030 |
Why?
| | Chromosomes, Artificial, Bacterial | 1 | 2017 | 22 | 0.030 |
Why?
| | Receptors, LDL | 1 | 2017 | 53 | 0.030 |
Why?
| | Gorilla gorilla | 1 | 2017 | 17 | 0.030 |
Why?
| | Workflow | 1 | 2018 | 182 | 0.030 |
Why?
| | Lymphocyte Count | 3 | 2002 | 167 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2018 | 391 | 0.030 |
Why?
| | ErbB Receptors | 1 | 2020 | 636 | 0.030 |
Why?
| | Elastin | 1 | 2017 | 78 | 0.030 |
Why?
| | Apolipoproteins E | 1 | 2017 | 97 | 0.030 |
Why?
| | Computer Simulation | 1 | 2021 | 1014 | 0.030 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2017 | 128 | 0.030 |
Why?
| | Health Equity | 1 | 2019 | 139 | 0.030 |
Why?
| | Proteolysis | 1 | 2017 | 174 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2017 | 5439 | 0.030 |
Why?
| | Quality-Adjusted Life Years | 1 | 2016 | 122 | 0.030 |
Why?
| | Cross Infection | 1 | 2019 | 258 | 0.030 |
Why?
| | Germ-Line Mutation | 1 | 2017 | 180 | 0.030 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2024 | 892 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2017 | 410 | 0.030 |
Why?
| | Liver | 1 | 2005 | 1864 | 0.030 |
Why?
| | Autoantibodies | 1 | 2023 | 1500 | 0.030 |
Why?
| | Antibodies, Monoclonal | 2 | 2018 | 1512 | 0.030 |
Why?
| | Respiratory Insufficiency | 1 | 2019 | 330 | 0.030 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 253 | 0.030 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2017 | 102 | 0.030 |
Why?
| | CD57 Antigens | 1 | 2015 | 18 | 0.030 |
Why?
| | Intention to Treat Analysis | 1 | 2015 | 78 | 0.030 |
Why?
| | Siberia | 1 | 2015 | 7 | 0.030 |
Why?
| | Nursing Staff | 1 | 2016 | 41 | 0.030 |
Why?
| | Evidence-Based Medicine | 1 | 2019 | 731 | 0.030 |
Why?
| | Americas | 1 | 2015 | 27 | 0.030 |
Why?
| | K562 Cells | 1 | 2015 | 93 | 0.030 |
Why?
| | History, Ancient | 1 | 2015 | 54 | 0.030 |
Why?
| | Leukemia, Myeloid | 1 | 2015 | 49 | 0.030 |
Why?
| | Down-Regulation | 1 | 2017 | 614 | 0.030 |
Why?
| | Adaptive Immunity | 1 | 2016 | 173 | 0.030 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2008 | 224 | 0.030 |
Why?
| | Patient Participation | 1 | 2019 | 457 | 0.030 |
Why?
| | Attitude | 1 | 2017 | 253 | 0.030 |
Why?
| | Databases, Genetic | 1 | 2016 | 239 | 0.030 |
Why?
| | Vascular Remodeling | 1 | 2017 | 208 | 0.030 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2001 | 1150 | 0.030 |
Why?
| | Fruit | 1 | 2015 | 144 | 0.030 |
Why?
| | Program Evaluation | 1 | 2019 | 952 | 0.030 |
Why?
| | Chromosomes, Mammalian | 1 | 2014 | 28 | 0.030 |
Why?
| | Tumor Suppressor Proteins | 1 | 2017 | 315 | 0.030 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2019 | 352 | 0.030 |
Why?
| | Smoking Prevention | 1 | 2015 | 168 | 0.030 |
Why?
| | DNA Damage | 1 | 2017 | 439 | 0.030 |
Why?
| | Vegetables | 1 | 2015 | 159 | 0.030 |
Why?
| | Genetic Fitness | 1 | 2015 | 60 | 0.030 |
Why?
| | Inpatients | 1 | 2019 | 540 | 0.030 |
Why?
| | Social Support | 1 | 2019 | 646 | 0.030 |
Why?
| | Patient Care Team | 1 | 2000 | 701 | 0.030 |
Why?
| | South Africa | 1 | 2015 | 262 | 0.030 |
Why?
| | Hypoglycemia | 1 | 2019 | 490 | 0.030 |
Why?
| | Terminology as Topic | 1 | 2016 | 253 | 0.030 |
Why?
| | Patient Education as Topic | 1 | 2019 | 770 | 0.030 |
Why?
| | Bone Marrow Transplantation | 1 | 2015 | 301 | 0.030 |
Why?
| | Models, Psychological | 1 | 2015 | 290 | 0.030 |
Why?
| | Caribbean Region | 1 | 2013 | 29 | 0.030 |
Why?
| | Mouth | 1 | 2014 | 84 | 0.020 |
Why?
| | Bone Marrow | 1 | 2015 | 310 | 0.020 |
Why?
| | Hepacivirus | 1 | 2015 | 237 | 0.020 |
Why?
| | Reproduction | 1 | 2015 | 209 | 0.020 |
Why?
| | Genetic Association Studies | 1 | 2015 | 379 | 0.020 |
Why?
| | Guidelines as Topic | 1 | 2015 | 267 | 0.020 |
Why?
| | Inflammation | 1 | 2025 | 2919 | 0.020 |
Why?
| | Transplant Recipients | 1 | 2015 | 177 | 0.020 |
Why?
| | United States | 2 | 2023 | 16136 | 0.020 |
Why?
| | Cultural Competency | 1 | 2014 | 83 | 0.020 |
Why?
| | Asia | 2 | 2003 | 69 | 0.020 |
Why?
| | Lung | 2 | 2019 | 4122 | 0.020 |
Why?
| | Ultrasonography | 1 | 2017 | 788 | 0.020 |
Why?
| | Ursidae | 1 | 2012 | 8 | 0.020 |
Why?
| | Smad Proteins | 1 | 2012 | 42 | 0.020 |
Why?
| | Cell Membrane | 1 | 2016 | 701 | 0.020 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2012 | 54 | 0.020 |
Why?
| | Acute Disease | 1 | 2015 | 1038 | 0.020 |
Why?
| | DNA, Mitochondrial | 1 | 2013 | 212 | 0.020 |
Why?
| | Genome | 1 | 2014 | 307 | 0.020 |
Why?
| | Host-Pathogen Interactions | 1 | 2015 | 366 | 0.020 |
Why?
| | Cattle | 1 | 2014 | 940 | 0.020 |
Why?
| | Physical Therapy Modalities | 1 | 1975 | 341 | 0.020 |
Why?
| | Feces | 1 | 2015 | 496 | 0.020 |
Why?
| | Quantitative Trait Loci | 1 | 2014 | 388 | 0.020 |
Why?
| | Smoking Cessation | 1 | 2015 | 442 | 0.020 |
Why?
| | Pregnancy Proteins | 1 | 2011 | 36 | 0.020 |
Why?
| | Family Practice | 1 | 1975 | 422 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2019 | 3416 | 0.020 |
Why?
| | Pulmonary Veins | 1 | 1992 | 110 | 0.020 |
Why?
| | Adaptation, Biological | 1 | 2011 | 48 | 0.020 |
Why?
| | Models, Biological | 2 | 2016 | 1761 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2016 | 1135 | 0.020 |
Why?
| | Immunologic Memory | 1 | 2013 | 369 | 0.020 |
Why?
| | HLA-A2 Antigen | 1 | 2011 | 36 | 0.020 |
Why?
| | Dogs | 1 | 2012 | 517 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 2019 | 1101 | 0.020 |
Why?
| | Aortic Aneurysm, Thoracic | 1 | 2012 | 135 | 0.020 |
Why?
| | Twins, Dizygotic | 2 | 2001 | 109 | 0.020 |
Why?
| | Twins, Monozygotic | 2 | 2001 | 133 | 0.020 |
Why?
| | MAP Kinase Signaling System | 1 | 2012 | 307 | 0.020 |
Why?
| | Uterus | 1 | 2011 | 227 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2012 | 384 | 0.020 |
Why?
| | Culture | 1 | 2011 | 122 | 0.020 |
Why?
| | HLA-A11 Antigen | 1 | 2009 | 1 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 1995 | 1998 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2017 | 2502 | 0.020 |
Why?
| | Antibody Affinity | 1 | 2009 | 60 | 0.020 |
Why?
| | Receptors, KIR2DL5 | 1 | 2009 | 1 | 0.020 |
Why?
| | Leucine | 1 | 2009 | 116 | 0.020 |
Why?
| | Substrate Specificity | 1 | 2009 | 389 | 0.020 |
Why?
| | Protein Structure, Secondary | 1 | 2009 | 356 | 0.020 |
Why?
| | Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2008 | 36 | 0.020 |
Why?
| | Pyridoxine | 1 | 2008 | 37 | 0.020 |
Why?
| | Personality Inventory | 1 | 2008 | 132 | 0.020 |
Why?
| | Clone Cells | 1 | 2008 | 259 | 0.020 |
Why?
| | Crystallography, X-Ray | 1 | 2009 | 477 | 0.020 |
Why?
| | Tryptophan | 1 | 2009 | 184 | 0.020 |
Why?
| | Aging | 1 | 2019 | 1996 | 0.020 |
Why?
| | Vitamin B 12 | 1 | 2008 | 140 | 0.020 |
Why?
| | Peptide Fragments | 1 | 2011 | 693 | 0.020 |
Why?
| | Hemodynamics | 1 | 2012 | 1114 | 0.020 |
Why?
| | Folic Acid | 1 | 2008 | 197 | 0.020 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2011 | 902 | 0.020 |
Why?
| | Microbiota | 1 | 2014 | 725 | 0.020 |
Why?
| | Lysine | 1 | 2009 | 303 | 0.020 |
Why?
| | Venezuela | 1 | 2006 | 7 | 0.020 |
Why?
| | Rabbits | 1 | 2007 | 651 | 0.010 |
Why?
| | Myeloid Cells | 1 | 2007 | 149 | 0.010 |
Why?
| | CD4-CD8 Ratio | 1 | 2005 | 23 | 0.010 |
Why?
| | CD8 Antigens | 1 | 2005 | 70 | 0.010 |
Why?
| | Placenta | 1 | 2011 | 794 | 0.010 |
Why?
| | Leukocyte Common Antigens | 1 | 2005 | 86 | 0.010 |
Why?
| | Microspheres | 1 | 2005 | 142 | 0.010 |
Why?
| | Cell Separation | 1 | 2005 | 300 | 0.010 |
Why?
| | Genetic Techniques | 1 | 2004 | 64 | 0.010 |
Why?
| | Immunophenotyping | 1 | 2005 | 324 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2008 | 1242 | 0.010 |
Why?
| | Oligonucleotide Probes | 1 | 2003 | 48 | 0.010 |
Why?
| | Membrane Proteins | 1 | 2009 | 1130 | 0.010 |
Why?
| | Postoperative Period | 1 | 2003 | 355 | 0.010 |
Why?
| | Cyclosporine | 1 | 2003 | 256 | 0.010 |
Why?
| | Genes, bcl-2 | 1 | 2002 | 21 | 0.010 |
Why?
| | Utah | 1 | 2002 | 82 | 0.010 |
Why?
| | Living Donors | 1 | 2003 | 216 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2008 | 1763 | 0.010 |
Why?
| | Chi-Square Distribution | 1 | 2001 | 517 | 0.010 |
Why?
| | Genes, BRCA1 | 1 | 2000 | 45 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 2000 | 161 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2018 | 17438 | 0.010 |
Why?
| | BRCA2 Protein | 1 | 2000 | 69 | 0.010 |
Why?
| | Immunosuppressive Agents | 1 | 2003 | 829 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 2001 | 1543 | 0.010 |
Why?
| | Ambulatory Care Facilities | 1 | 2000 | 269 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2000 | 1298 | 0.010 |
Why?
| | Autoimmune Diseases | 1 | 2000 | 467 | 0.010 |
Why?
| | Hospital Departments | 1 | 1975 | 9 | 0.010 |
Why?
| | Referral and Consultation | 1 | 2000 | 881 | 0.010 |
Why?
| | Receptors, Leukotriene B4 | 1 | 1992 | 7 | 0.010 |
Why?
| | SRS-A | 1 | 1992 | 17 | 0.010 |
Why?
| | Receptors, Leukotriene | 1 | 1992 | 13 | 0.010 |
Why?
| | Dicarboxylic Acids | 1 | 1992 | 12 | 0.010 |
Why?
| | Leukotriene E4 | 1 | 1992 | 24 | 0.010 |
Why?
| | Propionates | 1 | 1992 | 39 | 0.010 |
Why?
| | Transcription Factors | 1 | 2000 | 1730 | 0.010 |
Why?
| | Cysteine | 1 | 1992 | 210 | 0.010 |
Why?
| | Muscle Contraction | 1 | 1992 | 438 | 0.000 |
Why?
|
|
Norman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|